Aisling Capital related stories
All articles and analysis
Fund performance: Aberdare, Vicente, Aisling show gains in CalPERS portfolioInsight V leads the venture portfolio, Khosla III and Khosla Seed lose ground
VC-backed Versartis raises $126 mln for IPOVersartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "VSAR." Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.
- VC-backed Versartis raises $126 mln for IPO
Versartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "VSAR." Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.
- VC-backed Agile Therapeutics files for IPO
Agile Therapeutics has filed for an IPO. The number of shares that will be offered as well as the pricing terms of the stock have yet to be set. RBC Capital Markets and William Blair & Company will serve as the lead underwriters. Based in Princeton, NJ, Agile Therapeutics is a women's health specialty pharmaceutical company focused on developing prescription contraceptives. Its backers include Aisling Capital, Care Capital, Investor Growth Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.
- Versartis rakes in $55 mln in Series E funds
Versartis has closed $55 million in Series E financing. The investors include return backers Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency.
- Miramar Labs raises $10 mln in Series D funding
Miramar Labs, a medical device manufacturer, has raised $10 million in Series D funding. The funding round was led by Aisling Capital, Cross Creek Capital, Domain Associates, Morgenthaler Ventures and RusnanoMedInvest.
- Greater Cleveland tech companies attract $259mln in 2013
Last year, 118 tech-based companies in Greater Cleveland raised $259 million from venture capitalists and angel investors, according to the region's Venture Capital Advisory Task Force. This was a 15 percent percent increase over the amount attracted in 2012.
- ViewRay snags $30 mln
ViewRay has raised $30 million in funding. Investors included Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Cowealth Medical Holding Co. Debt financing was provided by Hercules Technology Growth Capital. Based in Cleveland, Ohio, ViewRay is a medical device company that develops advanced radiation therapy technology for treating cancer.
- Versartis raises $20 mln in Series D financing
Versartis has closed $20 million in Series D financing. Sofinnova Ventures was the lead investor. Return backers Advent Venture Partners' Advent Life Sciences fund, Aisling Capital, Amunix Operating Inc., Index Ventures and New Leaf Venture Partners also participated in this round. In conjunction with the funding Sofinnova's general partner Dr. Srinivas Akkaraju will join Versartis board of directors. Based in Redwood City, Calif., Versartis is a biotechnology company focused on developing treatments for patients with endocrine disorders.
- Loxo Oncology raises $33 mln in Series A financing
Loxo Oncology said Thursday that it has closed $33 million in Series A financing. Founding investor Aisling Capital and new investor OrbiMed Advisors participated in the round. In addition to the funding, Also, Loxo Oncology has formed a board of directors, which includes Steven Elms and Dr. Dov Goldstein, managing partner and partner at Aisling Capital, respectively, and Dr. David Bonita, private equity partner at OrbiMed Advisors. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.